BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2020 Earnings Results

Biocryst Pharmaceuticals Misses on EPS, Stock Down 0.82%

Biocryst Pharmaceuticals reported a loss of $0.26 per share, slightly missing expectations. The stock reacted negatively, declining by 0.82%. The lack of revenue figures and guidance may have contributed to investor uncertainty, reflecting ongoing challenges in the market.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.26	N/A	-2.36%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the company's performance. They highlighted ongoing challenges but did not provide specific guidance for future quarters.

Management did not provide specific revenue figures during the call.

The company acknowledged challenges in the current market environment.

Biocryst Pharmaceuticals Misses on EPS, Stock Down 0.82%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Misses on EPS, Stock Down 0.82%

Key numbers

Management commentary